Nasdaq

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
Mena FN

Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead The Charge In Pioneering New Treatments Delveinsight

DelveInsight's "Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy ...
Seeking Alpha

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
Business Wire

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced that TTHX1114 was ...
Yahoo

Focus on Eyes: Cloudy eyes, discomfort could be symptoms of Fuchs' dystrophy

Add Yahoo as a preferred source to see more of our stories on Google. In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a ...
News Medical

Study uncovers mechanisms behind Fuchs Endothelial Corneal Dystrophy

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...
Business Wire

Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery

CHICAGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 ...